Clinical Trial Results: Lymphomas

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) Alone and in Combination with Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Product Name: MabThera/Rituxan [rituximab]
Date of Report: 2/1/2007
Phase: II
A phase II, multicenter, open-label trial on the efficacy and safety of Rituximab therapy in patients with B-cell post-transplant lymphoproliferative disorders (B-PTLD) (organ or bone marrow transplant recipients) with progressive disease after immunosuppressive therapy reduction or discontinuation.

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Product Name: R7159
Date of Report: To be Published
Phase: II
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.